Atlas Trials

Gemcitabine Hydrochloride, Cisplatin, and Sunitinib Malate as First-Line Therapy in Treating Patients With Locally Advanced And/or Metastatic Transitional Cell Carcinoma of the Urothelium (SUCCINCT)

Clinical trial NCT01089088 · COMPLETED

Trial details

NCT number
NCT01089088
Sponsor
Cardiff University
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Bladder CancerTransitional Cell Cancer of the Renal Pelvis and UreterUrethral Cancer
Start date
2009-04-01
Primary completion
2014-10-01
Enrollment
63

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.